Xyzagen
UEI: X6RJTXBJHP95
• CAGE: 88NG5
Overview
Awardee Type
Parent
Federal Capability Statement
A boutique, client focused, contract research and consulting organization with a focus on 505(b)(1) and 505(b)(2) early discovery and clinical pharmacology & pharmacokinetics research, regulatory strategy & consulting. Xyzagen's labs support early in vitro and rodent pharmacokinetics, bioanalysis and pharmacology studies, while its consultants provide expert consulting in drug development and pharmacokinetic, toxicokinetic, clinical pharmacology and pharmacometric modeling.
Keywords
Research org. in early drug discovery & dev.
SBA Special Equipment
Phoenix WinNonLin, Sciex LC/MS/MS mass spectrometry systems, bioanalytical lab equipment, rodent pharmacology equipment, in vitro systems culturing.
Website
Headquarters
Pittsboro, NC
United States
United States
Federal recipient
XYZAGEN INC.
(UEI X6RJTXBJHP95, CAGE 88NG5)
is headquartered in Pittsboro NC.
Its primary registered NAICS is 541714 Research and Development in Biotechnology (except Nanobiotechnology).
The corporation
was founded in February 2018 and
federally registered in
January 2019.
Federal Registration and Certifications
Legal Name
XYZAGEN INC.
UEI
X6RJTXBJHP95
CAGE Code
88NG5
SBA Certifications
None
Self Certifications
Self-Certified Small Disadvantaged Business
Entity Structure
Corporate Entity (Not Tax Exempt)
Purpose of Registration
Federal Contracts and Assistance
Date Founded
Feb. 14, 2018
Initial Registration
Jan. 29, 2019
Last Registration
Dec. 3, 2025
Registration Activation
Dec. 3, 2025
Registration Expiration
Dec. 2, 2026
Fiscal Year End
December 31
Reported Entity Types
For Profit Organization
Subchapter S Corporation
Subchapter S Corporation
State of Incorporation
NC
Country of Incorporation
USA
Employees
<500
Reported NAICS
Reported PSC
Accepts Credit Cards
No